Tokyo, Sept. 2 (Jiji Press)–Fujitsu Ltd. <6702> and Tokyo Shinagawa Hospital said on Wednesday they have begun a research to develop artificial intelligence-based technology to speed up COVID-19 diagnosis.
The AI technology will be used to support the diagnostic imaging of coronavirus-linked pneumonia via computed tomography images of the chest, said the Japanese tech company and the hospital.
For the diagnosis of COVID-19, chest CT tests are being used together with polymerase chain reaction tests. But doctors have to check hundreds of images per patient to make lung disease diagnoses, which has been a heavy burden.
In the research project, the AI technology will learn from the characteristics of shadow patterns shown in CT images of COVID-19 patients, so that it can find possible coronavirus infections.
The developers did not comment on when the technology might be put to commercial use.
Fujifilm Corp. is developing AI-driven technology to help the diagnosis and evaluate the efficacy of treatments for COVID-19 based on chest CT images.
The Fujifilm Holdings Corp. <4901> unit aims to make the technology a product by the end of this year to prepare for a resurgence of coronavirus cases and possible spreads of other diseases in the future.
In May, NTT Data Corp. <9613> started testing an AI-based technology to support COVID-19 diagnosis at a hospital in India, together with a local startup. The company is working on research to improve its accuracy for possible use in Japan.